Investigative therapies to treat moderate to severe plaque psoriasis in clinical trials include several orally administered ...

A novel drug almost entirely cleared moderate to severe psoriasis in over 60% of the patients who took part in two phase three clinical trials of a new drug. The University of Manchester and Salford ...

Johnson & Johnson has won US approval for its new psoriasis drug, taking on the likes of Novartis, Eli Lilly and Valeant in an increasingly crowded market. The FDA has backed guselkumab ...

The company, based in Nijmegen, is developing both oral and topical RORγt drug candidates for psoriasis and other autoimmune diseases. The market for new psoriasis and related immunology ...

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the New Drug Application (NDA) of its internally-developed IL-17-targeting monoclonal antibody gumokimab (AK111) has been ...

Stull said that a number of prescription treatments exist for topical psoriasis, such as steroids and injectable therapies, ...

The US plans to slash the price it pays for the Novo Nordisk A/S blockbusters Ozempic and Wegovy, the latest drugs to be ...

Johnson & Johnson beat Wall Street’s fourth-quarter expectations as strong cancer drug sales compensated for a decline in ...

On Friday, the U.S. Department of Health and Human Services (HHS) unveiled the selection of 15 additional drugs covered under ...